Feed / AZTA

Azenta, Inc.

AZTA

Healthcare · 30.17 +0.0% today

Isolated · not yet confirmedMarket checked 10 Sept, 15:55 GMT-4

Market read

Azenta, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 12 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.

Company+0.0% todayVolume comparison unavailable
Market group0 of 12 activeEquity Risk · unavailable
Disclosed network0 of 5 confirmingNo filing-linked name is confirming now
What would change this read
  • AZTA's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if AZTA's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Medical Instruments & Supplies

No new filing conclusion is available. 0 of 12 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • AZTA's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations319
Usable filing statements96
Verified relationships4
Evidence supporting the case
  • Operating margin changed +4.4 percentage points in the latest annual period.
  • Net margin changed +19.4 percentage points in the latest annual period.
Evidence challenging the case
  • Product pipeline and R&D has repeated adverse evidence across 4 filings.
  • Restructuring and cost reductions has repeated adverse evidence across 3 filings.
Questions before a position
  • EV/sales is 89% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 10, 2026

30.17
6m+11.8%12m-0.1%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-09-30$513.7M+32.2%$1.49+0.8%
2022-09-30$555.5M+8.1%$28.48+0.6%
2023-09-30$551.5M-0.7%$-0.22-11.5%
2024-09-30$573.4M+4.0%$-3.10-19.7%
2025-09-30$593.8M+3.6%$-1.22-13.7%

What management says matters

Persistent and emerging business drivers

Product pipeline and R&Dnegative · 4 filings
39 Table of Contents Research and Development Expenses Our research and development expenses for the three months ended December 31, 2025 and 2024 are as follows: ​ Three Months Ended December 31, ​ 2025 2024 ​ In thousands % of Revenue In thousands % of Reve…
10-Q · Feb 5, 2026
Restructuring and cost reductionsnegative · 3 filings
The increased net loss from continuing operations was primarily driven by the non-cash goodwill impairment charge of $149.1 million, partially offset by lower income tax expense.
10-Q · May 8, 2026
Capital investment and capacitymixed · 1 filings
Cash inflows from investing activities were $224.7 million for fiscal year 2024 and consisted of $666.2 million of sales and maturities of marketable securities, partially offset by $405.6 million for purchases of marketable securities and $37.4 million of ca…
10-K · Dec 4, 2025
Input and raw-material costsmixed · 1 filings
The increases in gross margin and adjusted gross margin were primarily driven by higher gross margin for the Next Generation Sequencing and Gene Synthesis, partially offset by lower gross margin for Sanger sequencing services.
10-K · Dec 4, 2025

Valuation discipline

Descriptive valuation snapshot

Price/sales 2.3× · EV/sales 1.9×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

30.17+0.0% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for AZTA. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for AZTA. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind AZTA

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

TMOThermo Fisher Scientific Inc.competitorDec 4, 2025

In the Sample Management Solutions segment, our main competitors include Hamilton Company and Liconic AG for automation systems and Laboratory Corporation of America Holdings and Thermo Fisher Scientific Inc.

TWSTTwist Bioscience CorporationcompetitorDec 4, 2025

In the Multiomics segment, our main competitors include BGI Genomics Co., Ltd., Eurofins, Scientific S.E., GenScript Biotech Corporation, Integrated DNA Technologies, Inc., Novogene Co., Ltd., and Twist Bioscience Corporation.

Depended on by

CYRXCryoport, Inc.competitorMar 5, 2026

Life Sciences Products competition is with companies offering cryogenic systems products such as Azenta Life Sciences, Phase 2, and IC Biomedical.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 9 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

AZTA is currently a Participant in the organic co-movement group Equity Risk. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for AZTA; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.